Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder.
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Mirabegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
- 28 Jul 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov
- 28 Jul 2011 Planned end date changed from 1 Jan 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov record.